



HEXIMA

Press Release

Hexima Limited

ABN 64 079 319 314

Level 5, 114 William Street
Melbourne Vic 3000

Telephone 61 3 8629 2999

Facsimile 61 3 8629 2990

Hexima extends research program targeting human applications

16 November 2009 Hexima reports promising early stage results in its externally-funded human disease program. The program is still considered to be in the discovery stage at this time. The Company is encouraged by its initial findings and has determined to undertake the next stage of research, which will determine whether any of the molecules of interest progress into clinical trials over the next 2-3 years. The Board proposes to obtain funding in the order of \$2 million for this project.

For more information, please contact:

Joshua Hofheimer
Chief Executive Officer
Hexima Limited
Telephone +61 3 8629 2999

About Hexima

Hexima Limited (ASX Code: HXL) is an agribusiness company developing innovative gene technologies to help farmers enhance the productivity of arable land by improving yields and reducing the use of chemicals. Hexima's core technologies aim to strengthen commercial crops by enhancing their resistance to insect pests and fungal disease. Hexima partners with multinational seed companies to establish commercial markets for its technologies.

Visit www.hexima.com.au for more information.

For personal use only